Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: 5,17,37,5,101,... who wrote (168)	1/3/1999 6:03:00 PM
From: tnsaf	Read Replies (1) \| Respond to of 2515

Jackson, have a look at IMCL's web site for a description of how C255 is used: imclone.com It states "C225 is a chimerized (part mouse, part human) monoclonal antibody that acts as a cancer therapeutic to block the Epidermal Growth Factor receptor (EGFr). Blocking the EGFr on tumor cells should result in an arrest of tumor growth, which can "prime" the tumor to respond to other previously mentioned cancer modalities, such as chemotherapy and radiation therapy. EGFr is over-expressed on greater than one-third of all solid cancers. Current clinical studies for patients with EGFr positive tumors include breast, renal cell, pancreatic, and head and neck cancers." Jason